Abstract:203 Background: Cetuximab (CTX) and Panitumumab (PMB) therapies directed at EGFR have been restricted to left-sided CRC harboring wild-type KRAS ( KRAS WT ), limiting their utility. Approximately 50% of mCRC fail to respond to EGFRi, thus identification of predictive biomarkers is an unmet need. Here we evaluate a CTX sensitivity score (CTX-S) that we previously reported (Yang M. et al., 2019), in a large, real-world population of RAS/BRAF mutant vs wild-type and in right- vs left-sided tumors. Methods: CTX/PMB-treated CRC specimens (n=1124) with clinical outcomes, NextGen Sequencing of DNA (592-gene panel or whole exome sequencing) and RNA (whole transcriptome sequencing) were tested at Caris Life Sciences (Phoenix, AZ). 1097 specimens were MSS as determined by IHC of MMR proteins and/or NGS. Association of CTX-S with RAS/BRAF mutation and tumor sidedness was performed in MSS tumors. Tumors with likely pathogenic mutations in KRAS, NRAS or BRAF were considered as RAS MUT /BRAF MUT , or RAS WT /BRAF WT if no mutation was detected for each gene. Samples were stratified based on CTX-S quintiles. Survival on EGFRi was calculated from the initiation of EGFRi to last contact using Kaplan-Meir method. Results: Higher CTX-S quintiles were significantly associated with longer survival on EGFRi in RAS/BRAF wild-type as well as -mutant subpopulations. Similar results were seen in left- vs. right-sided tumors (Table). Higher CTX-S quintiles were associated with a survival benefit in all CMS classes but CMS2; however, the vast majority of CMS2 tumors (460/467) were among the top 3 CTX-S quintiles. As the median survival among the top 3 quintiles was ~2-fold higher than the bottom 2 quintiles, we used stratification by the 40 th percentile for the genomic analysis. CTX-S >40 th percentile was associated with an increased prevalence in APC (91 vs 47%) and TP53 (93 vs 76%) mutations and decreased prevalence in BRAF (6 vs 32%), SMAD4 (8 vs 19%), RNF43 (1 vs 12%) and ATM (2 vs 5%) mutations (all q<0.05). Conclusions: Our data suggest that CTX-S may predict longer survival on EGFRi, surprisingly independent of RAS/BRAF mutation status as well as tumor sidedness. Patients with high CTX-S had increased prevalence of CMS2 and harbored more APC and TP53 mutations. A strong EGFRi biomarker would likely expand the utility of EGFRi to right-sided tumors and possibly to RAS MUT tumors. Further validation of these biomarkers in a prospective clinical trial is warranted and could change our current standard of care for CRC.[Table: see text]

Current status and perspective of drug treatment on left-side and right-side colon cancer

Different Treatment Strategies and Molecular Features Between Right-Sided and Left-Sided Colon Cancers

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

The Optimal First-Line Treatment for Patients with Left-Sided RAS Wild-Type Metastatic Colorectal Cancer: Double-drug Regimen or Triple-Drug Regimen Therapy

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

Impact of Primary Tumor Side on Clinical Outcomes of First-Line Cetuximab Plus FOLFOX-4 in RAS Wild-Type Metastatic Colorectal Cancer.

Patients with RAS Wild-Type Right-Sided Unresectable Liver-Confined Mcrc Also Benefit from Cetuximab Plus Chemotherapy in First-Line Treatment

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.

Transverse colon primary tumor location as a biomarker in metastatic colorectal cancer: A pooled analysis of CCTG/AGITG CO.17 and CO.20 randomized clinical trials

Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis

Should Anti-Egfr Mabs Be Discontinued for Conversion Surgery in Untreated Right-Sided Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis.

High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.

Comparison and treatment of left-and right-side colon cancer

Distinguishable Prognostic Signatures of Left- and Right-Sided Colon Cancer: a Study Based on Sequencing Data

Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients

Right- and Left-Sided Colorectal Cancers Respond Differently to Cetuximab

Superior survival in right-sided versus left-sided colon signet ring cell carcinoma

Phase II APEC Trial: the Impact of Primary Tumor Side on Outcomes of First‐line Cetuximab Plus FOLFOX or FOLFIRI in Patients with RAS Wild‐type Metastatic Colorectal Cancer

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF -mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI ☆

Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories